

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
Ali AMARA et al.)	Group Art Unit: 1648
)	
Application No.: 10/700,491)	Examiner: Stacy Brown CHEN
)	
Filed: November 5, 2003)	Confirmation No.: 6283
)	
For: COMPOSITIONS COMPRISING DC-)	
SIGN BLOCKERS AND METHODS)	
OF USING DC-SIGN BLOCKERS)	
FOR PREVENTING OR TREATING)	
DISEASES OF A MAMMAL,)	
INCLUDING VIRAL INFECTIONS)	
)	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed before the mailing date of a first Office Action after the filing of a Request for Continued Examination in the above-referenced application.

Copies of the listed foreign and non-patent literature documents are attached. Copies of patent application numbers 10/464,531 and 10/700,507 were previously submitted on May 26, 2005, but the Examiner did not initial the PTO/SB/08 form to indicate that they were considered. Applicants are not resubmitting copies here, but would be happy to do so at the Examiner's request. Applicants note that the Examiner

indicated in the previous Office Action that the applications had been considered.

Applicants respectfully submit that, upon consideration of the references, initialing of the PTO/SB/08 is appropriate and request that the examiner do so. See MPEP 609 ("There is no requirement that the information submitted must be prior art references in order to be considered by the Examiner. . . . The initials of the Examiner placed adjacent to the citations on the PTO-1449 or PTO/SB/08A and 08B or its equivalent mean that the information has been considered by the examiner")

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claims in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: December 22, 2005

By: 
Kenneth J. Meyers
Reg. No. 25,146

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

2

Application Number	10/700,491
Filing Date	November 5, 2003
First Named Inventor	Ali AMARA et al.
Art Unit	1648
Examiner Name	Stacy Brown CHEN
Attorney Docket Number	03495.0300

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-4,522,811	06-11-1985	Eppstein et al.	
		US-4,683,195	07-28-1987	Mullis et al.	
		US-4,683,202	07-28-1987	Mullis	
		US-5,223,409	06-29-1993	Ladner et al.	
		US-5,403,484	04-04-1995	Ladner et al.	
		US-5,498,538	03-12-1996	Kay et al.	
		US-5,516,637	05-14-1996	Huang et al.	
		US-5,571,698	11-05-1996	Ladner et al.	
		US-5,625,033	04-29-1997	Kay et al.	
		US-5,658,727	08-19-1997	Barbas et al.	
		US-5,667,988	09-16-1997	Barbas et al.	

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		EP 1046651 A1	10/25/2000	Figdor et al.		
		WO 91/05876 A1	05/02/1991	Gehrz et al.		
		WO 00/63251	10/26/2000	KATHOLIEKE UNIVERSITEIT NIJMEGEN		
		WO 93/01820	02/04/1993	BRISTOL-MYERS SQUIBB COMPANY		
		WO 02/080851 A2	10/17/2002	THE JOHNS HOPKINS UNIVERSITY		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
		Desrosiers, R., "Prospects for an AIDS Vaccine," <i>Nature Medicine</i> , 10(3):221-233 (2004)	
		Feinberg et al, "AIDS Vaccine Models: Challenging Challenge Viruses," <i>Nature Medicine</i> , 9(3):207-210 (2002).	
		Greene, W., "The Brightening Future of HIV Therapeutics," <i>Nature Immunology</i> , 4(9):867-871 (2004).	
		Halary et al.; "HUMAN CYTOMEGALOVIRUS BINDING TO DC-SIGN IS REQUIRED FOR DENDRITIC CELL INFECTION AND TARGET CELL TRANS-INFECTION"; <i>Immunity</i> , Vol. 17, No. 5, pages 653-664, (2002)	
		Kwon et al.; "DC-SIGN-MEDIATED INTERNALIZATION OF HIV IS REQUIRED FOR TRANS-ENHANCEMENT OF T CELL INFECTION"; <i>Immunity</i> , Vol. 16, No. 1, pages 135-144, (2002)	
		MacDonald et al., "Mucosal and Parenteral Vaccination Against Acute and Latent MCMV," <i>J. Virology</i> , 72(1):442-451 (1998).	
		Navarro-Sanchez et al.; "DENDRITIC-CELL-SPECIFIC ICAM3-GRABBING NON-INTEGRIN IS ESSENTIAL FOR THE PRODUCTIVE INFECTION OF HUMAN DENDRITIC CELLS BY MOSQUITO-CELL-DERIVED	

IDS Form PTO/SB/08: Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		<i>Application Number</i>	10/700,491
		<i>Filing Date</i>	November 5, 2003
		<i>First Named Inventor</i>	Ali AMARA et al.
		<i>Art Unit</i>	1648
		<i>Examiner Name</i>	Stacy Brown CHEN
<i>Attorney Docket Number</i>	03495.0300		
Sheet	2	of	2

NON PATENT LITERATURE DOCUMENTS			
		DENGUE VIRUSES"; EMBO Reports, Vol. 4, No. 7, pages 723-728, (2003)	
		Tassaneetrithep et al.; "DC-SING (CD209) MEDIATES DENGUE VIRUS INFECTION OF HUMAN DENDRITIC CELLS"; Journal of Experimental Medicine, Vol. 197, No. 7, pages 823-829, (2003)	
		Wang et al., "Recombinant Modified Vaccinia Virus Ankara Expressing a Soluble Form of Glycoprotein B, <i>J. Virology</i> , 78(8):3965-3976 (2004).	
		Copy of Office Action dated December 28, 2004 in Application No. 10/700,507 (Identified by Attorney Docket No. 03495.0301).	
		Copy of Office Action dated October 17, 2005 in Application No. 10/700,507 (Identified by Attorney Docket No. 03495.0301).	
		Patent Application No. 10/464,531 of Olivier NEYROLLES, Olivier SCHWARTZ, Ludovic TAILLEUX , and Philippe LAGRANGE, filed June 19, 2003 (identified by Attorney Docket No. 03495.0270).	
		Patent Application No. 10/700,507 of Ali AMARA, Frank HALARY, Julie DECHANET-MERVILLE, Jean-Francois MOREAU, Fernando ARENZANA-SEISDEDOS and Thierry DELAUNAY, filed November 5, 2003 (Identified by Attorney Docket No. 03495.0301).	
		Copy of WO 2004/041299 A1 published May 21, 2004, which entered the National Stage in Application No. 10/533,924 (Identified by Attorney Docket No. 03495.0337).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.